Translational psychiatry

Long-term effects of magnesium-ibogaine treatment in special operations veterans with traumatic brain injuries

Updated

Abstract

Of 30 participants treated with magnesium-ibogaine, 25 completed the 12-month follow-up assessments.

  • Significant reductions in functional disability and psychiatric symptoms, including PTSD, depression, and anxiety, were observed up to 12 months post-treatment.
  • Linear mixed-effects models indicated robust and sustained improvements, with all results showing strong statistical significance (p < 0.001).
  • Large effect sizes were recorded, with Cohen's d values of 2.18 or greater at the 12-month mark.
  • Survival analyses suggested that the probability of sustained remission at 12 months was 84% for PTSD, 66% for depression, and 61% for anxiety in those who achieved remission immediately after treatment.
  • Most participants reported the use of other psychedelic substances or interventions during the follow-up, which could influence long-term outcomes.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free